{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:00:55Z","timestamp":1762077655209,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ahj.2014.06.014","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T10:54:57Z","timestamp":1403780097000},"page":"611-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?"],"prefix":"10.1016","volume":"168","clinical-trial-number":[{"clinical-trial-number":"nct01433627","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kurt","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric R.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen Dalby","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Lopez Sendon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tubaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.06.014_bb0005","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0015","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0020","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"Anticoagulants in heart disease\u2014current status and perspectives. Section I\u2014general background on coagulation and targets of anticoagulants","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.014_bb0030","first-page":"572","article-title":"Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective","volume":"106","author":"Faxon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.014_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.014_bb0040","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non\u2013ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1160\/TH13-06-0453","article-title":"Differences between ACC\/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes","volume":"110","author":"Huber","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.014_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0060","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.06.014_bb0065","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0070","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0075","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.111.075242","article-title":"Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven","volume":"125","author":"Krishna","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.014_bb0080","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/hrt.2010.201889","article-title":"Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy","volume":"96","author":"Smit","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2014.06.014_bb0085","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","article-title":"Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome","volume":"55","author":"ten Berg","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0090","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0095","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0100","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.06.014_bb0105","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.2010.1320","article-title":"Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA\/OASIS-8 randomized trial","volume":"304","author":"Steg","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.06.014_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/joic.12005","volume":"26","author":"Waksman","year":"2013","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.06.014_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2013.09.027","article-title":"Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: the HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0125","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0130","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0135","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","article-title":"Facilitated PCI in patients with ST-elevation myocardial infarction","volume":"358","author":"Ellis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0140","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.06.014_bb0155","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2008.09.060","article-title":"Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI randomized trial","volume":"53","author":"Fung","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0160","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0165","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0170","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0175","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.06.014_bb0180","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.06.014_bb0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(09)61454-9","article-title":"Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial","volume":"374","author":"Sabatine","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.06.014_bb0190","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jama.2013.277165","article-title":"Anticoagulation with otamixaban and ischemic events in non\u2013ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial","volume":"310","author":"Steg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.06.014_bb0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0205","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0210","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH11-08-0602","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe","volume":"106","author":"Huber","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.014_bb0215","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000353674","article-title":"Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?","volume":"126","author":"Niazi","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.ahj.2014.06.014_bb0220","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0225","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0230","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0240","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0245","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0250","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0255","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0260","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.014_bb0265","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2010.07.004","article-title":"Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0270","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"Valgimigli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.014_bb0275","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jcin.2013.06.010","article-title":"Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease","volume":"6","author":"Viviani Anselmi","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.06.014_bb0280","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcin.2012.01.007","article-title":"Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y12 inhibitor therapeutic window","volume":"5","author":"Tantry","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.06.014_bb0285","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.jacc.2008.12.073","article-title":"Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice","volume":"53","author":"Doyle","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.014_bb0290","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/eurheartj\/ehs012","article-title":"The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non\u2013ST-segment elevation myocardial infarction","volume":"33","author":"Lopes","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.014_bb0295","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.06.014_bb0300","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.014_bb0305","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.111.060871","article-title":"Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"125","author":"Ndrepepa","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.014_bb0310","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.014_bb0315","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","article-title":"Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention","volume":"4","author":"Verheugt","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2014.06.014_bb0320","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2014.06.014_bb0325","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2012.06.017","article-title":"Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study","volume":"60","author":"Romagnoli","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314003640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314003640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:55:58Z","timestamp":1762077358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870314003640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0002870314003640"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.06.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}